Joseph Yeboah1, Tamar S Polonsky2, Rebekah Young2, Robyn L McClelland2, Joseph C Delaney2, Farah Dawood2, Michael J Blaha2, Michael D Miedema2, Christopher T Sibley2, J Jeffrey Carr2, Gregory L Burke2, David C Goff2, Bruce M Psaty2, Philip Greenland2, David M Herrington2. 1. From Heart and Vascular Center of Excellence, Wake Forest Baptist Health, Winston Salem, NC (J.Y., F.D., D.M.H.); Section of Cardiology, Department of Internal Medicine, University of Chicago, IL (T.S.P.); Department of Biostatistics (R.Y., R.L.M., J.C.D.) and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services (B.M.P.), University of Washington, Seattle; Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (M.J.B.); Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, MN (M.D.M.); Radiology, Oregon Health and Science University, Portland (C.T.S.); Radiology, Vanderbilt University School of Medicine, Nashville, TN (J.J.C.); Public Health, Wake Forest University School of Medicine, Winston Salem, NC (G.L.B.); Public Health, University of Colorado School of Public Health, Aurora (D.C.G.); Group Health Research Institute, Group Health Cooperative, Seattle, WA (B.M.P.); and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (P.G.). jyeboah@wakehealth.edu. 2. From Heart and Vascular Center of Excellence, Wake Forest Baptist Health, Winston Salem, NC (J.Y., F.D., D.M.H.); Section of Cardiology, Department of Internal Medicine, University of Chicago, IL (T.S.P.); Department of Biostatistics (R.Y., R.L.M., J.C.D.) and Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services (B.M.P.), University of Washington, Seattle; Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (M.J.B.); Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, MN (M.D.M.); Radiology, Oregon Health and Science University, Portland (C.T.S.); Radiology, Vanderbilt University School of Medicine, Nashville, TN (J.J.C.); Public Health, Wake Forest University School of Medicine, Winston Salem, NC (G.L.B.); Public Health, University of Colorado School of Public Health, Aurora (D.C.G.); Group Health Research Institute, Group Health Cooperative, Seattle, WA (B.M.P.); and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (P.G.).
Abstract
BACKGROUND: In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. METHODS AND RESULTS: Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE <7.5% and elevated levels of additional risk markers (abnormal test) whose new calculated risk was ≥7.5% were considered statin eligible: low-density lipoprotein cholesterol ≥160 mg/dL; family history of ASCVD; high-sensitivity C-reactive protein ≥2 mg/dL; coronary artery calcium score ≥300 Agatston units or ≥75th percentile for age, sex, and ethnicity; and ankle-brachial index <0.9. We compared the absolute and relative ASCVD risks among those with versus without elevated posttest estimated risk. We calculated the number needed to screen to identify 1 person with abnormal test for each risk marker, defined as the number of participants with baseline cPCE risk <7.5% divided by the number with an abnormal test reclassified as statin eligible. Of 5185 participants not taking statins with complete data (age, 45-84 years), 4185 had a cPCE risk <7.5%. During 10 years of follow-up, 57% of the ASCVD events (183 of 320) occurred among adults with a cPCE risk <7.5%. When people with diabetes mellitus were excluded, the coronary artery calcium criterion reclassified 6.8% upward, with an event rate of 13.3%, absolute risk of 10%, relative risk of 4.0 (95% confidence interval [CI], 2.8-5.7), and number needed to screen of 14.7. The corresponding numbers for family history of ASCVD were 4.6%, 15.1%, 12%, 4.3 (95% CI, 3.0-6.4), and 21.8; for high-sensitivity C-reactive protein criteria, 2.6%, 10%, 6%, 2.6 (95% CI, 1.4-4.8), and 39.2; for ankle-brachial index criteria, 0.6%, 9%, 5%, 2.3 (95% CI, 0.6-8.6), and 176.5; and for low-density lipoprotein cholesterol criteria, 0.5%, 5%, 1%, 1.2 (95% CI, 0.2-8.4), and 193.3, respectively. Of the 3882 with <7.5% cPCE risk, 431 (11.1%) were reclassified to ≥7.5% (statin eligible) by at least 1 of the additional risk marker criteria. CONCLUSIONS: In this generally low-risk population sample, a large proportion of ASCVD events occurred among adults with a 10-year cPCE risk <7.5%. We found that the coronary artery calcium score, high-sensitivity C-reactive protein, family history of ASCVD, and ankle-brachial index recommendations by the American College of Cardiology/American Heart Association cholesterol guidelines (Class IIB) identify small subgroups of asymptomatic population with a 10-year cPCE risk <7.5% but with observed ASCVD event rates >7.5% who may warrant statin therapy considerations.
BACKGROUND: In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk assessment in those below this threshold for statin therapy is unclear. METHODS AND RESULTS: Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample free of clinical CVD at baseline, we calibrated the Pooled Cohort Equations (cPCE). ASCVD was defined as myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke. Adults with an initial cPCE <7.5% and elevated levels of additional risk markers (abnormal test) whose new calculated risk was ≥7.5% were considered statin eligible: low-density lipoprotein cholesterol ≥160 mg/dL; family history of ASCVD; high-sensitivity C-reactive protein ≥2 mg/dL; coronary artery calcium score ≥300 Agatston units or ≥75th percentile for age, sex, and ethnicity; and ankle-brachial index <0.9. We compared the absolute and relative ASCVD risks among those with versus without elevated posttest estimated risk. We calculated the number needed to screen to identify 1 person with abnormal test for each risk marker, defined as the number of participants with baseline cPCE risk <7.5% divided by the number with an abnormal test reclassified as statin eligible. Of 5185 participants not taking statins with complete data (age, 45-84 years), 4185 had a cPCE risk <7.5%. During 10 years of follow-up, 57% of the ASCVD events (183 of 320) occurred among adults with a cPCE risk <7.5%. When people with diabetes mellitus were excluded, the coronary artery calcium criterion reclassified 6.8% upward, with an event rate of 13.3%, absolute risk of 10%, relative risk of 4.0 (95% confidence interval [CI], 2.8-5.7), and number needed to screen of 14.7. The corresponding numbers for family history of ASCVD were 4.6%, 15.1%, 12%, 4.3 (95% CI, 3.0-6.4), and 21.8; for high-sensitivity C-reactive protein criteria, 2.6%, 10%, 6%, 2.6 (95% CI, 1.4-4.8), and 39.2; for ankle-brachial index criteria, 0.6%, 9%, 5%, 2.3 (95% CI, 0.6-8.6), and 176.5; and for low-density lipoprotein cholesterol criteria, 0.5%, 5%, 1%, 1.2 (95% CI, 0.2-8.4), and 193.3, respectively. Of the 3882 with <7.5% cPCE risk, 431 (11.1%) were reclassified to ≥7.5% (statin eligible) by at least 1 of the additional risk marker criteria. CONCLUSIONS: In this generally low-risk population sample, a large proportion of ASCVD events occurred among adults with a 10-year cPCE risk <7.5%. We found that the coronary artery calcium score, high-sensitivity C-reactive protein, family history of ASCVD, and ankle-brachial index recommendations by the American College of Cardiology/American Heart Association cholesterol guidelines (Class IIB) identify small subgroups of asymptomatic population with a 10-year cPCE risk <7.5% but with observed ASCVD event rates >7.5% who may warrant statin therapy considerations.
Authors: Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs Journal: Circulation Date: 2010-11-15 Impact factor: 29.690
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Maryam Kavousi; Suzette Elias-Smale; Joost H W Rutten; Maarten J G Leening; Rozemarijn Vliegenthart; Germaine C Verwoert; Gabriel P Krestin; Matthijs Oudkerk; Moniek P M de Maat; Frank W G Leebeek; Francesco U S Mattace-Raso; Jan Lindemans; Albert Hofman; Ewout W Steyerberg; Aad van der Lugt; Anton H van den Meiracker; Jacqueline C M Witteman Journal: Ann Intern Med Date: 2012-03-20 Impact factor: 25.391
Authors: Michael H Criqui; Robyn L McClelland; Mary M McDermott; Matthew A Allison; Roger S Blumenthal; Victor Aboyans; Joachim H Ix; Gregory L Burke; Kaing Liu; Steven Shea Journal: J Am Coll Cardiol Date: 2010-10-26 Impact factor: 24.094
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Joseph Yeboah; Robyn L McClelland; Tamar S Polonsky; Gregory L Burke; Christopher T Sibley; Daniel O'Leary; Jeffery J Carr; David C Goff; Philip Greenland; David M Herrington Journal: JAMA Date: 2012-08-22 Impact factor: 56.272
Authors: Mahmoud Al Rifai; Miguel Cainzos-Achirica; Sina Kianoush; Mohammadhassan Mirbolouk; Allison Peng; Josep Comin-Colet; Michael J Blaha Journal: Curr Treat Options Cardiovasc Med Date: 2018-09-26
Authors: Sina Kianoush; Mahmoud Al Rifai; Miguel Cainzos-Achirica; Priya Umapathi; Garth Graham; Roger S Blumenthal; Khurram Nasir; Michael J Blaha Journal: Curr Atheroscler Rep Date: 2016-03 Impact factor: 5.113
Authors: Wendy M White; Michelle M Mielke; Philip A Araoz; Brian D Lahr; Kent R Bailey; Muthuvel Jayachandran; Virginia M Miller; Vesna D Garovic Journal: Am J Obstet Gynecol Date: 2016-02-10 Impact factor: 8.661